Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,  
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–25428 Filed 10–28–13; 8:45 am]  
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Centers for Disease Control and Prevention

Board of Scientific Counselors,  
National Center for Injury Prevention and Control, (BSC, NCIPC)

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces, the following meeting of the aforementioned committee:

Time and Date: 8:30 a.m.–4:30 p.m.  
Eastern Time, November 15, 2013.  
Place: Teleconference.

Status: The meeting is open to the public; the toll free dial in number is 1–877–937–9818 and the passcode is 7551384.  
Purpose: The board makes recommendations regarding policies, strategies, objectives, and priorities, and reviews progress toward injury prevention goals and provides evidence in injury prevention-related research and programs.  
The board provides advice on the appropriate balance of intramural and extramural research, and provides advice on the structure, progress and performance of intramural programs. The Board of Scientific Counselors is also designed to provide guidance on extramural scientific program matters, including the: (1) Review of extramural research concepts for funding opportunity announcements; (2) conduct of Secondary Peer Review of extramural research grants, cooperative agreements, and contracts applications received in response to the funding opportunity announcements as it relates to the Center’s programmatic balance and mission; (3) submission of secondary review recommendations to the Center Director of applications to be considered for funding support; (4) review of research portfolios, and (5) review of program proposals. The board shall provide guidance on the National Center of Injury Prevention and Control’s programs and research activities by conducting scientific peer review of intramural research and programs within the National Center for Injury Prevention and Control; by ensuring adherence to Office of Management and Budget requirements for intramural peer review; and by monitoring the overall direction, focus, and success of the National Center for Injury Prevention and Control.

Matters to be Discussed: The BSC, NCIPC will discuss the recommendations provided by the expert panel on the Health Communication Portfolio Review that has been conducted and to discuss research strategies needed to guide the Center’s focus. The BSC members will also discuss potential topics for the upcoming Portfolio Review. There will be 15 minutes allotted for public comments at the end of the open session. Agenda items are subject to change as priorities dictate.


The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,  
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2013–25427 Filed 10–28–13; 8:45 am]  
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Food and Drug Administration

Food and Drug Administration  
[Docket No. FDA–2013–N–0001]  
Request for Nominations for Voting Members on a Public Advisory Committee; Tobacco Products Scientific Advisory Committee  
AGENCY: Food and Drug Administration, HHSC.  
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for voting members to serve on the Tobacco Products Scientific Advisory Committee, Office of Science, Center for Tobacco Products.  
FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.

DATES: Nominations received on or before December 30, 2013, will be given first consideration for membership on the Tobacco Products Scientific Advisory Committee. Nominations received after December 30, 2013, will be considered for nomination to the committee as later vacancies occur.

ADDRESSES: All nominations for membership should be sent electronically to cv@oc.fda.gov or by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993–0002.

FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for membership, the primary contact is:  

Information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA’s Web site by using the following link: http://www.fda.gov/AdvisoryCommittees/default.htm.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting members on the Tobacco Products Scientific Advisory Committee. Elsewhere in this issue of the Federal Register, FDA is publishing a separate document announcing the Request for Nominations for Nonvoting Industry Representatives on the Tobacco Products Scientific Advisory Committee.

I. General Description of the Committee Duties

The Tobacco Products Scientific Advisory Committee advises the Commissioner or designee in discharging responsibilities as they relate to the regulation of tobacco products. The Committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides appropriate advice, information, and recommendations to the Commissioner of Food and Drugs.

II. Criteria for Voting Members

The Committee shall consist of 12 members including the Chair. Members and the Chair are selected by the Commissioner or designee from among individuals knowledgeable in the fields of medicine, medical ethics, science, or technology involving the manufacture, evaluation, or use of tobacco products. Members will be invited to serve for overlapping terms of up to 4 years. Almost all non-Federal members of this committee serve as Special Government Employees. The Committee shall include nine technically qualified voting members, selected by the Commissioner or designee. The nine voting members shall be physicians, dentists, scientists, or health care professionals practicing in the area of oncology, pulmonology, cardiology,
toxicology, pharmacology, addiction, or any other relevant specialty.

In addition to the voting members, the committee shall include three nonvoting members who are identified with industry interests. These members shall include one representative of the tobacco manufacturing industry, one representative of the interests of tobacco growers, and one representative of the interests of the small business tobacco manufacturing industry.

III. Nomination Procedures

Any interested person may nominate one or more qualified individuals for membership on the advisory committee. Self-nominations are also accepted. Nominations must include a current, complete résumé or curriculum vitae for each nominee, including current business address and/or home address, telephone number, and email address if available. Nominations must also specify the advisory committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: October 21, 2013.

Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, October 11, 2013, 10:00 a.m. to 5:00 p.m., National Institutes of Health, Two Democracy Plaza, Suite 950, 6707 Democracy Boulevard, Bethesda, MD 20892, which was published in the Federal Register on July 26, 2013, 78 FR 45254.

The meeting notice is amended to change the date from October 22, 2013, to November 19–20, 2013 at 8:00 a.m. to 6:00 p.m. The location remains the same. The meeting is closed to the public.

Dated: October 23, 2013.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, October 22, 2013, 11:00 a.m. to 5:00 p.m., National Institutes of Health, Two Democracy Plaza, Suite 951, 6707 Democracy Boulevard, Bethesda, MD 20892, which was published in the Federal Register on September 10, 2013, 78 FR 55268.

The meeting notice is amended to change the date from October 22, 2013, to December 11, 2013. The time and location remains the same. The meeting is closed to the public.

Dated: October 24, 2013.

Carolyn A. Baum,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel, October 23, 2013, 8:00 a.m. and will end on November 22, 2013 at 1:00 p.m. The meeting is closed to the public.

Dated: October 23, 2013.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Tumor Cell Biology Study Section, October 16, 2013, 08:00 a.m. to October 17, 2013, 05:00 p.m., Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115 which was published in the Federal Register on September 17, 2013, 78 FR 57169.

The meeting will be held at the National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. The meeting will start on November 16, 2013 at 8:00 a.m. and end on November 17, 2013 at 7:00 p.m. The meeting is closed to the public.

Dated: October 23, 2013.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, October 11, 2013, 08:00 a.m. to October 11, 2013, 05:00 p.m., Doubletree Hotel Washington, 1515 Rhode Island Ave. NW., Washington, DC 20005 which was published in the Federal Register on September 11, 2013, 78 FR Pgs. 55752–55753.

The meeting will be held at National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892. The meeting will start on November 15, 2013 at 9:00 a.m. and end on November 15, 2013 at 4:00 p.m. The meeting is closed to the public.